Literature DB >> 19544704

Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis.

Badira Makhoul1, Eyal Braun, Moshe Herskovitz, Rawi Ramadan, Salim Hadad, Krivoy Norberto.   

Abstract

BACKGROUND: West Nile virus, the etiologic agent of West Nile fever, is an emerging mosquito-borne disease. WNV was recognized as a cause of severe human meningoencephalitis in elderly patients during outbreaks in various parts of the world.
OBJECTIVES: To analyze WNV encephalitis therapy and its outcome after prescribing hyperimmune gammaglobulin therapy.
METHODS: Eight subjects with WNV encephalitis were treated with supportive therapy and 5 days of IVIG 0.4 g/kg/day containing high WNV antibodies obtained from healthy blood donors.
RESULTS: Patients who were treated with IVIG as soon as possible exhibited an improvement in their symptoms. All subjects presented with high fever, progressive confusion and headaches, nausea and vomiting. The Glasgow Coma Screen for six patients ranged between 8 and 13 and all were discharged with a score of 15. The remaining two subjects died during their hospitalization.
CONCLUSIONS: In severe WNV infection, where the disease affects the central and/or peripheral nervous system, early intervention with IVIG together with supportive treatment is recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544704

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  13 in total

1.  Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis.

Authors:  Ruchi Srivastava; Chandran Ramakrishna; Edouard Cantin
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

2.  West Nile encephalitis mimicking neuropsychiatric lupus in a patient with systemic lupus erythematosus.

Authors:  Neena R Iyer; W Joseph McCune; Beth I Wallace
Journal:  BMJ Case Rep       Date:  2019-07-24

3.  A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.

Authors:  Julie E Ledgerwood; Theodore C Pierson; Sarah A Hubka; Niraj Desai; Steve Rucker; Ingelise J Gordon; Mary E Enama; Steevenson Nelson; Martha Nason; Wenjuan Gu; Nikkida Bundrant; Richard A Koup; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2011-03-11       Impact factor: 5.226

Review 4.  The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade.

Authors:  Nina Svetlicky; Oscar-Danilo Ortega-Hernandez; Luc Mouthon; Loic Guillevin; Hans-Jurgen Thiesen; Arie Altman; Martine Szyper Kravitz; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2012-12-11       Impact factor: 8.317

Review 5.  Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features.

Authors:  Drew J Winston; Holenarasipur R Vikram; Ingrid B Rabe; Gundeep Dhillon; David Mulligan; Johnny C Hong; Ronald W Busuttil; Marek J Nowicki; Thomas Mone; Rachel Civen; Selam A Tecle; Kavita K Trivedi; Susan N Hocevar
Journal:  Transplantation       Date:  2014-05-15       Impact factor: 4.939

Review 6.  Emerging Cases of Powassan Virus Encephalitis in New England: Clinical Presentation, Imaging, and Review of the Literature.

Authors:  Anne Piantadosi; Daniel B Rubin; Daniel P McQuillen; Liangge Hsu; Philip A Lederer; Cameron D Ashbaugh; Chad Duffalo; Robert Duncan; Jesse Thon; Shamik Bhattacharyya; Nesli Basgoz; Steven K Feske; Jennifer L Lyons
Journal:  Clin Infect Dis       Date:  2015-12-13       Impact factor: 9.079

7.  The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.

Authors:  Yuko Muraki; Takeshi Fujita; Masaaki Matsuura; Isao Fuke; Sadao Manabe; Toyokazu Ishikawa; Yoshinobu Okuno; Kouichi Morita
Journal:  Virol J       Date:  2015-04-09       Impact factor: 4.099

8.  Cytokine responses and correlations thereof with clinical profiles in children with enterovirus 71 infections.

Authors:  Ning Ye; Xun Gong; Li-li Pang; Wen-juan Gao; Ya-ting Zhang; Xiao-le Li; Na Liu; Dan-di Li; Yu Jin; Zhao-jun Duan
Journal:  BMC Infect Dis       Date:  2015-06-11       Impact factor: 3.090

9.  May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis?

Authors:  Daniel Růžek; Gerhard Dobler; Hans Helmut Niller
Journal:  BMC Infect Dis       Date:  2013-07-03       Impact factor: 3.090

10.  The clinical response of West Nile virus neuroinvasive disease to intravenous immunoglobulin therapy.

Authors:  Zvi Shimoni; Hanna Bin; Shlomo Bulvik; Mark Niven; Rawi Hazzan; Ella Mendelson; Paul Froom
Journal:  Clin Pract       Date:  2012-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.